Wechselwirkungen · Descovy
Descovy 200 mg/10 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 12
HOS-134975 · Präparat HOS-097638
Ethinylestradiol: AUC: ↔ Cmin: ↔ Cmax: ↔ SEDATIVES/HYPNOTICS Orally administered midazolam Midazolam: No dose adjustment of midazolam (2.5 mg single dose), tenofovir AUC: ↔ is required. Dose Descovy alafenamide (25 mg once daily) Cmax: ↔ according to the concomitant Intravenously administered Midazolam: antiretroviral (see section 4.2). midazolam (1 mg single dose), AUC: ↔ tenofovir alafenamide (25 mg Cmax: ↔ once daily) 1 When doses are provided, they are the doses used in clinical drug-drug interaction studies. 2 When data are available from drug-drug interaction studies. 3 Study conducted with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fixed-dose combination tablet. 4 Study conducted with emtricitabine/rilpivirine/tenofovir alafenamide fixed-dose combination tablet. 5 Study conducted with Descovy. 6 Emtricitabine/tenofovir alafenamide was taken with food in this study. 7 Study conducted with additional voxilaprevir 100 mg to achieve voxilaprevir exposurers expected in HCV-infected patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) cobicistat (HOS-088111) voxilaprevir (HOS-108930) rilpivirine (HOS-088090) elvitegravir (HOS-088110) midazolam (HOS-086167)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2023-02-17T15:13:00Z · SHA-256 a11fc916e5e96ef11eeda5a56230a79328fb44e76134aa071c19126c22c2e943 · Passage 3f54142468f505375fe0b6ce5fc06f42e53418b4530bdba6e9545c4383417b6a · Zeichen 22163–23513 im Abschnitt